肥胖的神经代谢和神经炎症后果:洞察大脑脆弱性和基于成像的生物标志物
Miloš Vuković1, Igor Nosek1, Milica Medić Stojanoska1
1Faculty of Medicine, University in Novi Sad, 21000 Novi Sad, Serbia.
International journal of molecular sciences
|January 28, 2026
概括
肥胖通过炎症和胰岛素抵抗损害大脑,导致认知问题. 先进的神经成像揭示了这些动态变化,为保护大脑健康的干预提供了希望.
科学领域:
- 神经学 神经学
- 代谢障碍 代谢障碍 代谢障碍
- 神经炎症是一种神经炎症.
背景情况:
- 肥胖是一种与慢性炎症和胰岛素抵抗相关的全身代谢疾病.
- 大脑是肥胖的脆弱目标器官,经历结构和功能变化.
- 这些变化导致认知障碍和神经退行性疾病的风险增加.
研究的目的:
- 审查与肥胖相关的大脑脆弱性的神经代谢和神经炎症机制.
- 探索先进的神经成像如何有助于理解这些大脑变化.
- 讨论早期风险分层和治疗策略的可能性.
主要方法:
- 现有文献的叙述性审查.
- 检查神经代谢和神经炎症路径.
- 对先进的神经成像技术 (MRI,PET) 的分析.
主要成果:
- 肥胖导致特定区域的大脑变化,影响执行功能,奖励处理和食欲调节.
- 关键机制包括神经炎症,胰岛素信号受损,线粒体功能障碍,氧化应激,BBB干扰和清除受损.
- 多模式神经成像揭示了动态的,潜在的可修改的大脑变化.
结论:
- 与肥胖相关的大脑脆弱性涉及复杂的神经代谢和神经炎症过程.
- 神经成像为体内大脑的改变提供了关键的见解.
- 整合生物标志物可能会增强风险分层,并指导用于保护大脑健康的干预措施.
相关概念视频
Obesity
1.3K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
Timing and Consequences on Behavior
378
In operant conditioning, the timing of reinforcement is crucial. For animals like rats and cats, immediate reinforcement (within a few seconds) is much more effective than delayed reinforcement. For example, a food reward for a rat needs to follow within 30 seconds of pressing a bar to be effective.
Humans, however, can respond to delayed reinforcers. We often make decisions between immediate small rewards and delayed larger rewards. This ability to delay gratification is a significant...
Humans, however, can respond to delayed reinforcers. We often make decisions between immediate small rewards and delayed larger rewards. This ability to delay gratification is a significant...
378
Brain Imaging
727
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
727
Drug Dosing: Obese Patients
254
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
254
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
266
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
266
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
176
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
176


